Drug Information

Drug (ID: DG02003) and It's Reported Resistant Information

Name	Imexon
Synonyms	(S)-Imexon\|Imexon, (S)-\|N691NU86WU\|1,3-Diazabicyclo(3.1.0)hex-3-en-2-one, 4-amino-, (5S)-\|1018810-26-8\|UNII-N691NU86WU\|Q27284609 Click to Show/Hide
Indication	In total 1 Indication(s) . . .
Structure
Drug Resistance Disease(s)	Disease(s) with Clinically Reported Resistance for This Drug (1 diseases) Oral squamous cell carcinoma [ICD-11: 2B6E] [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	C4H5N3O
IsoSMILES	C1[C@@H]2N1C(=O)NC2=N
InChI	InChI=1S/C4H5N3O/c5-3-2-1-7(2)4(8)6-3/h2H,1H2,(H2,5,6,8)/t2-,7?/m0/s1
InChIKey	BIXBBIPTYBJTRY-VBMBUWLQSA-N
PubChem CID	135564735

Type(s) of Resistant Mechanism of This Drug

MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Oral squamous cell carcinoma [ICD-11: 2B6E]

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Metabolic Reprogramming via Altered Pathways (MRAP)		Click to Show/Hide
Key Molecule: Histone H3			[1]
Metabolic Type	Glucose metabolism
Resistant Disease	Oral squamous cell carcinoma [ICD-11: 2B6E.0]		Disease Info
Molecule Alteration	Lactylation	.	Molecule Info
Experimental Note	Identified from the Human Clinical Data
In Vivo Model	OSCC samples		Homo Sapiens
Mechanism Description	We found that histone Kla-induced BCAM was overexpressed in OSCC, and a high BCAM level was related to a lower immune cell score and inhibition of immune response. On the other hand, BCAM induced EMT and angiogenesis, leading to OSCC malignant progression via activating the Notch signaling pathway. However, the difference of the BCAM function in Pan-cancers might be attributed to tumor heterogeneity. Taken together, BCAM played a vital role in OSCC chemotherapy resistance and prognosis and contributed to inhibition of the immune process, suggesting that it might be a novel therapeutic target for OSCC.

References

Ref 1	Histone Lysine Lactylation (Kla)-induced BCAM Promotes OSCC Progression and Cis-Platinum Resistance. Oral Dis. 2025 Apr;31(4):1116-1132.